Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans
- 30 October 2003
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 350 (3), 161-164
- https://doi.org/10.1016/s0304-3940(03)00895-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptideInternational Journal of Neuropsychopharmacology, 2001
- Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivoProceedings of the National Academy of Sciences, 2001
- Statins and the risk of dementiaThe Lancet, 2000
- Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasisProceedings of the National Academy of Sciences, 1998
- Aβ1–40 but not Aβ1–42 levels in cortex correlate with apolipoprotein E ϵ4 allele dosage in sporadic Alzheimer's diseaseBrain Research, 1997
- Aβ‐peptide length aid apolipoprotein E genotype in Alzheimer's diseaseAnnals of Neurology, 1996
- Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's diseaseNeurology, 1995
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993